Resource Library
Access publications, videos, websites and other up-to-date information about our products and therapy areas.
BioMarin is committed to supporting healthcare professionals with a range of information and resources to assist in the management of patients with rare diseases.
Achondroplasia is a rare genetic bone growth disorder and the most common form of disproportionate short stature. It is caused by a change in the fibroblast growth factor receptor 3 (FGFR3) gene, which impairs the growth of bone in the cartilage of the growth plate.
Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH).
Late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease is an ultra-rare and rapidly progressive paediatric brain disorder and one of the most common forms of neuronal ceroid lipofuscinosis, a group of inherited disorders collectively known as Batten disease.
Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy syndrome, is an ultra-rare inherited lysosomal storage disorder caused by the deficiency of N-acetylgalactosamine-4-sulfatase (arylsulfatase B), an enzyme required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs).
Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome, is an ultra-rare inherited lysosomal storage disorder caused by the deficiency of N-acetylgalactosamine-6-sulfatase (GALNS), an enzyme required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs).
Please select a product to access further information.
BRINEURA® is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
KUVAN® is indicated for the treatment of hyperphenylalaninemia (HPA) in sapropterin-responsive adult and paediatric patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.
NAGLAZYME® is indicated for the treatment of Mucopolysaccharidosis type VI (MPS VI) storage disorder, a disease in which the enzyme level of Nacetylgalactosamine 4-sulfatase is absent or lower than normal.
PALYNZIQ® is indicated for the treatment of patients with phenylketonuria (PKU) aged 16 and older, whose blood phenylalanine levels cannot be adequately controlled by other means such as by diet.
VIMIZIM® is indicated for the treatment of MPS IVA (mucopolysaccharidosis type IVA, morquio A syndrome).
VOXZOGO® is indicated for the treatment of achondroplasia in paediatric patients whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Access publications, videos, websites and other up-to-date information about our products and therapy areas.
BioMarin Pharmaceutical Australia Pty Ltd
119 Willoughby Rd, Crows Nest, NSW 2065, Australia
Email: anz@bmrn.com
Registered pharmacies and hospitals only:
Patients and consumers should speak to their community pharmacy or prescriber for more information.
Australia
DHL Direct to Market
Toll Free: 1800 077 421 (Option 1)
Email: d2mcs@dhl.com
New Zealand
Healthcare Logistics
Ph: 09 969 0734
E-mail: orders@healthcarelogistics.co.nz
Hours: 24 hrs/day, 7 days/week
Email: Medinfo@bmrn.com
Australia
Toll Free: 1800 387 876
Local: 02 8520 3255
New Zealand
Toll Free: 0800 882 012
Local: 09 801 1051
Hours: 24 hrs/day, 7 days/week
Email: Medinfo@bmrn.com
Submit an Adverse Event ›
Australia
Toll Free: 1800 387 876
Local: 02 8520 3255
New Zealand
Toll free: 0800 882 012
Local: 09 801 1051
TGA adverse event reporting
Website: www.tga.gov.au/reporting-problems
Registered pharmacies and hospitals only:
Australia
DHL Direct to Market
Toll Free: 1800 077 421 (Option 3)
Email: d2mcs@dhl.com
New Zealand
Healthcare Logistics
Ph: 09 969 0734
Email: orders@healthcarelogistics.co.nz
Email: anz@bmrn.com
Email: ir@bmrn.com
Tel: +1 (415) 455-7558